




FOR IMMEDIATE RELEASE

Pion Inc. launches the NEW MacroFLUX technology at AAPS.



Billerica, MA, USA—December 12, 2016—Participants at AAPS were able to see the newest addition to the FLUX family of products. Building on the success and effectiveness of Pion's PAMPA and μ FLUX, Pion continues to invest in and develop solutions for biorelevant data.

Unveiling at AAPS

Customers at APPS in Denver got to see the MacroFLUX up close for the first time. Vice President of Sales, Dave Kwajewski, said, "This has been a record year for Pion attendees at the AAPS booth. We truly believe the innovative science behind MacroFLUX was a big reason why."



Customers from across the pharmaceutical industry showed great interest in the MacroFLUX product line. Many of these customers have utilized Pion Fiber Optics in both dissolution and μ FLUX. The MacroFLUX brings two unique uses into one actualized product.



Following the launch of μ FLUX in 2013, Pion customers immediately pushed for larger volumes and more relevant situations. Using specific feedback from customers, Pion developed the MacroFLUX as a first step toward more biorelevant in vitro testing.

At AAPS, Konstantin Tsinman, CSO of Pion, presented [Using Integrated Absorption Chamber with USP II Dissolution Apparatus to Predict Risk of Drug-Drug Interaction from pH Modifying Agents.](#)

Customers throughout Pharma attended the presentation with very positive and enthusiastic feedback. Visit [Pion's web site](#) for the list of all posters presented at AAPS.

Customer Response to FLUX Technology

"Unique technique—would not get the answer any other way!"

"Many thanks for the excellent presentation and discussion on MacroFLUX."

"Pion has developed an innovative tool with many potential applications. Excited to see where it goes!"

About the MacroFLUX

The need to test finished drug products for their absorption potential in order to predict pharmacokinetic performance has been a topic of great interest to the drug development community. In many cases, dissolution experiments alone cannot correctly predict the *in vivo* response to drug products due to the complicated



interplay of solubility and permeability in complex media. Pion's MacroFLUX device extends the utility of *in situ* concentration monitoring to improve assessment of absorption potential and more realistic IVIVC modeling.

Introducing a stirred absorption chamber into the traditional USP I and II apparatus allows this type of testing to be done *in vitro* through the use of the MacroFLUX dissolution system. The USP vessel is the donor compartment, allowing for the volumes needed to test finished dosage forms under sink conditions. Using *in situ* fiber optic UV detection in both the donor and receiver provides the required data density for accurate assessment of transmembrane FLUX. For more information about Pion MacroFLUX systems or to order, contact sales@pion-inc.com.

About Pion Inc.

Pion Inc. develops and manufactures instrumentation for compound testing in pharmaceutical R&D. These include high-precision fiber optic-based analytical instruments for solubility and dissolution measurements, as well as complete systems for permeability (PAMPA), solubility, and ionization. Pion provides CRO services for solubility, permeability, dissolution, pK_a, and lipophilicity testing. Additionally, the new Lab Equipment Services department provides qualification and repair services for HPLC, dissolution, fiber optics, and more. Information is available at www.pion-inc.com.

For more information, please contact:
Barb Schwartz / Content and Marketing Manager
bschwartz@pion-inc.com
+1-919-264-3099

#